PerformanceInvestigational

ACE-031 (Ramatercept)

Subcutaneous injection

Overview

ACE-031 is a recombinant fusion protein combining the extracellular domain of the activin receptor type IIB with a human IgG1 Fc domain. This soluble receptor acts as a decoy to bind and neutralize myostatin, activin, and other negative regulators of muscle growth.

Mechanism of Action

By inhibiting these TGF-beta superfamily ligands, ACE-031 was designed to promote muscle hypertrophy in conditions characterized by muscle wasting..

Research Summary & Key Findings

Phase 2 clinical trials in postmenopausal women and healthy volunteers demonstrated dose-dependent increases in muscle mass and decreases in fat mass. Development was voluntarily suspended in 2013 following observations of adverse effects on skin vasculature, including telangiectasias and epistaxis. No subsequent clinical trials have been registered or published.

Clinical Status

Investigational

ACE-031 (Ramatercept) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injection

Related Peptides in Performance

Find a Provider

Find a verified provider who offers ACE-031 (Ramatercept) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply ACE-031 (Ramatercept).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.